Usman Shehzad: Transforming Patient Lives with INR Self-Testing
Usman Shehzad, Sales And Marketing Executive, Near Patient Care at Diagnostic Division Roche Diagnostics, Pakistan, shared a post on LinkedIn:
“Transforming Patient Lives with INR Self-Testing.
Key takeaways
INR self-testing gives patients greater control over their health and reduces anxiety during critical situations. Patients experience better quality of life by monitoring their health on their own schedules, avoiding the hassle that comes with traditional clinic visits
INR self-testing is a proactive approach that minimizes complications and helps patients on long-term or life-long anti-coagulation therapy.
When it comes to truly patient-centered care, self-testing is at the heart of healthcare transformation. Empowering individuals to take control of their health, self-testing enhances convenience, autonomy, and overall quality of life.
Today we highlight the experience of Truus Mommers, a vibrant 66-year-old from Venlo, Netherlands, whose story exemplifies the life-changing impact of INR self-testing on patients managing chronic coagulation conditions.
The Patient-Centric Benefits of INR Self-Testing
Diagnosed with deep vein thrombosis two decades ago, Truus initially found the condition overwhelming. But then she found self-testing which quickly became a turning point in her journey.
For patients like Truus, self-testing offers a sense of independence that traditional testing methods cannot match. It eliminates the need for frequent clinic visits, allowing patients with thrombosis to monitor their international normalized ratio (INR) levels at their own convenience.
Truus highlights the freedom this provides, enabling her to manage her business and maintain an active social life.
Beyond convenience, INR self-testing fosters a greater sense of control. Truus can perform unscheduled tests when she feels it’s necessary, providing immediate clarity and reassurance. This proactive approach often leads to reduced anxiety.”
Stay updated with Hemostasis Today.
-
Sep 9, 2026, 14:30Alejandro González Veliz: 2026 ESC Guidelines Expand Cardiac Rehabilitation Beyond Post-Event Recovery
-
Sep 9, 2026, 13:59Natalie Arnold: Biomarkers and the Hidden Burden of CHD
-
Sep 9, 2026, 13:11Ron DePinho: A Negative Trial Does Not Repudiate Inflammation as a Cardiovascular Target
-
Sep 9, 2026, 13:10Ahmad Gharehbaghian: Visiting the Alborz Provincial Blood Transfusion Center
-
Sep 9, 2026, 13:09Oraianthi Fiste: New Collection on Cancer-Associated Thrombosis From Mechanisms to Precision Medicine
-
Sep 9, 2026, 13:07Can Özlü: Can the HALP Score Help Identify Thrombotic Risk in Myeloproliferative Neoplasms?
-
Sep 9, 2026, 13:06Ohanna Cavalcanti Bezerra: Why Does DVT Lead to PE in Some Patients but Not Others?
-
Sep 9, 2026, 13:02Edward Lee Carter: Provoked VTE May Not Tell the Whole Story About Recurrence Risk
-
Sep 9, 2026, 13:01Danielle Charissa: Functional Genomics Reveals a Causal TWIST1 Variant in Cardiovascular Disease